Patents by Inventor Mary Rusckowski
Mary Rusckowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10537650Abstract: The invention relates to novel multi-modality probes for imaging, tracking and analyzing stem cells and related biological samples, and methods of preparation and use thereof. The molecular probes of the invention are constructed, for example, by utilizing (a) the high selectivity of long hydrocarbon chains for binding to plasma membranes of cells, (b) a near-infrared (NIR) dye for optical imaging, and (c) a radionuclide for PET or SPECT imaging. The in vitro and in vivo data of the optical and radiolabeled probes demonstrated their utility for detecting the presence of stem cells with multiple imaging modalities.Type: GrantFiled: November 14, 2016Date of Patent: January 21, 2020Assignee: University of MassachusettsInventors: Brian D. Gray, Mary Rusckowski, Koon Y. Pak
-
Publication number: 20180228925Abstract: Methods of monitoring and diagnosing subjects with motor neuron pathology such as motor neuron disorders (including but not limited to amyotrophic lateral sclerosis (ALS)) and neuropathies, based on imaging of a labeled fragment of tetanus toxin, e.g., tetanus toxin C fragment.Type: ApplicationFiled: August 26, 2016Publication date: August 16, 2018Inventors: Robert H. Brown, JR., Justin Pin-Tsun Lee, Mary Rusckowski
-
Publication number: 20170239377Abstract: The invention relates to novel multi-modality probes for imaging, tracking and analyzing stem cells and related biological samples, and methods of preparation and use thereof. The molecular probes of the invention are constructed, for example, by utilizing (a) the high selectivity of long hydrocarbon chains for binding to plasma membranes of cells, (b) a near-infrared (NIR) dye for optical imaging, and (c) a radionuclide for PET or SPECT imaging. The in vitro and in vivo data of the optical and radiolabeled probes demonstrated their utility for detecting the presence of stem cells with multiple imaging modalities.Type: ApplicationFiled: November 14, 2016Publication date: August 24, 2017Inventors: Brian D. Gray, Mary Rusckowski, Koon Y. Pak
-
Patent number: 9492571Abstract: The invention relates to novel multi-modality probes for imaging, tracking and analyzing stem cells and related biological samples, and methods of preparation and use thereof. The molecular probes of the invention are constructed, for example, by utilizing (a) the high selectivity of long hydrocarbon chains for binding to plasma membranes of cells, (b) a near-infrared (NIR) dye for optical imaging, and (c) a radionuclide for PET or SPECT imaging. The in vitro and in vivo data of the optical and radiolabeled probes demonstrated their utility for detecting the presence of stem cells with multiple imaging modalities.Type: GrantFiled: May 27, 2013Date of Patent: November 15, 2016Assignee: University of MassachusettsInventors: Brian D. Gray, Mary Rusckowski, Koon Y. Pak
-
Publication number: 20150125388Abstract: The invention relates to novel multi-modality probes for imaging, tracking and analyzing stem cells and related biological samples, and methods of preparation and use thereof. The molecular probes of the invention are constructed, for example, by utilizing (a) the high selectivity of long hydrocarbon chains for binding to plasma membranes of cells, (b) a near-infrared (NIR) dye for optical imaging, and (c) a radionuclide for PET or SPECT imaging. The in vitro and in vivo data of the optical and radiolabeled probes demonstrated their utility for detecting the presence of stem cells with multiple imaging modalities.Type: ApplicationFiled: May 27, 2013Publication date: May 7, 2015Applicant: Vniversity of Massachusetts Medical SchoolInventors: Brian D. Gray, Mary Rusckowski, Koon Y. Pak
-
Publication number: 20110158913Abstract: The present invention relates, in part, to detectably labeled oligomer duplexes and their use in optical imaging, including, in vivo optical imaging. The invention includes methods of optical imaging including in vivo pretargeting methods and in vivo antisense optical imaging methods.Type: ApplicationFiled: January 18, 2008Publication date: June 30, 2011Applicant: University of MassachusettsInventors: Don Hnatowich, Kayoko Nakamura, Yi Wang, Xinrong Liu, Jiang He, Surong Zhang, Mary Rusckowski
-
Patent number: 7560227Abstract: The present invention provides compositions suitable for use as biomarkers of vulnerable plaques as well as methods for the use of such compositions. In preferred embodiments, specific molecular imaging agents are provided that permit the selective identification of vulnerable plaques in coronary and other arteries using non-invasive imaging methods. Such specific molecular imaging agents comprise a binding partner linked to a detectable label that can be used in vivo to visualize vulnerable plaques. In certain preferred embodiments, the binding partner is a peptide that binds selectively to a component of a vulnerable plaque. In other preferred embodiments, the binding partner is an antibody that binds selectively to a component of a vulnerable plaque. In other preferred embodiments, the binding partner is a portion of a polypeptide displayed by a bacteriophage that binds selectively to a component of a vulnerable plaque.Type: GrantFiled: February 28, 2006Date of Patent: July 14, 2009Assignee: University of MassachusettsInventors: Young H. Kim, Ducksoo Kim, Mary Rusckowski
-
Publication number: 20070207507Abstract: The present invention provides compositions suitable for use as biomarkers of vulnerable plaques as well as methods for the use of such compositions. In preferred embodiments, specific molecular imaging agents are provided that permit the selective identification of vulnerable plaques in coronary and other arteries using non-invasive imaging methods. Such specific molecular imaging agents comprise a binding partner linked to a detectable label that can be used in vivo to visualize vulnerable plaques. In certain preferred embodiments, the binding partner is a peptide that binds selectively to a component of a vulnerable plaque. In other preferred embodiments, the binding partner is an antibody that binds selectively to a component of a vulnerable plaque. In other preferred embodiments, the binding partner is a portion of a polypeptide displayed by a bacteriophage that binds selectively to a component of a vulnerable plaque.Type: ApplicationFiled: February 28, 2006Publication date: September 6, 2007Applicant: University of MassachusettsInventors: Young Kim, Ducksoo Kim, Mary Rusckowski
-
Publication number: 20050255043Abstract: Labeled bacteriophage are disclosed which are useful for detecting a bacterial infection in vivo.Type: ApplicationFiled: April 8, 2005Publication date: November 17, 2005Inventors: Donald Hnatowich, Mary Rusckowski
-
Patent number: 6899864Abstract: The present invention provides a kit and a method for targeting of a diagnostic or therapeutic agent to a target site in a mammal having a pathological condition. The kit comprises, in separate containers, (a) a first conjugate comprising a targeting moiety and a Morpholino oligomer, wherein the targeting moiety selectively binds to a primary, target-specific binding site of the target site or to a substance produced by or associated with the target site; (b) optionally, a clearing agent; and (c) a second conjugate comprising a complementary Morpholino oligomer and a diagnostic agent or therapeutic agent. The method comprises administering (a), optionally (b), and (c) to a mammal.Type: GrantFiled: April 1, 2002Date of Patent: May 31, 2005Assignee: Immunomedics, Inc.Inventors: Donald J. Hnatowich, Mary Rusckowski, Guozheng Liu
-
Publication number: 20030003102Abstract: The present invention provides a kit and a method for targeting of a diagnostic or therapeutic agent to a target site in a mammal having a pathological condition. The kit comprises, in separate containers, (a) a first conjugate comprising a targeting moiety and a Morpholino oligomer, wherein the targeting moiety selectively binds to a primary, target-specific binding site of the target site or to a substance produced by or associated with the target site; (b) optionally, a clearing agent; and (c) a second conjugate comprising a complementary Morpholino oligomer and a diagnostic agent or therapeutic agent. The method comprises administering (a), optionally (b), and (c) to a mammal.Type: ApplicationFiled: April 1, 2002Publication date: January 2, 2003Applicant: University of MassachusettsInventors: Donald J. Hnatowich, Mary Rusckowski, Guozheng Liu
-
Patent number: 5980861Abstract: Compositions of radiolabeled nucleic acids and methods for synthesis and use thereof are disclosed.Type: GrantFiled: March 12, 1996Date of Patent: November 9, 1999Assignee: University of MassachusettsInventors: Donald J. Hnatowich, Mary Rusckowski, George Mardirossian, Paul Winnard, Jr., Fengchun Chang
-
Patent number: 5965133Abstract: The invention is directed to constructs and compositions containing multimeric forms of nucleic acid. Multimeric nucleic acids comprise single-stranded nucleic acids attached via biotin to streptavidin and bound with a functional group. These constructs can be utilized in vivo to treat or identify diseased tissue or cells. Repeated administrations of multimeric nucleic acid compositions produce a rapid and specific amplification of nucleic acid constructs and their attached functional groups. For treatment purposes, functional groups may be toxins, radioisotopes, genes or enzymes. Diagnostically, labeled multimeric constructs may be used to identify specific targets in vivo or in vitro. Multimeric nucleic acids may also be used in nanotechnology and to create self-assembling polymeric aggregates such as membranes of defined porosity, microcircuits and many other products.Type: GrantFiled: November 7, 1997Date of Patent: October 12, 1999Assignees: Trustees of Boston University, Univ. of Mass. Medical CenterInventors: Charles R. Cantor, Christof M. Niemeyer, Cassandra L. Smith, Takeshi Sano, Donald J. Hnatowich, Mary Rusckowski
-
Patent number: 5561043Abstract: The invention is directed to constructs and compositions containing multimeric forms of nucleic acid. Multimeric nucleic acids comprise single-stranded nucleic acids attached via biotin to streptavidin and bound with a functional group. These constructs can be utilized in vivo to treat or identify diseased tissue or cells. Repeated administrations of multimeric nucleic acid compositions produce a rapid and specific amplification of nucleic acid constructs and their attached functional groups. For treatment purposes, functional groups may be toxins, radioisotopes, genes or enzymes. Diagnostically, labeled multimeric constructs may be used to identify specific targets in vivo or in vitro. Multimeric nucleic acids may also be used in nanotechnology and to create self-assembling polymeric aggregates such as membranes of defined porosity, microcircuits and many other products.Type: GrantFiled: January 31, 1994Date of Patent: October 1, 1996Assignee: Trustees of Boston UniversityInventors: Charles R. Cantor, Christof M. Niemeyer, Cassandra L. Smith, Takeshi Sano, Donald J. Hnatowich, Mary Rusckowski